$5.08
+0.00 (+0.00%)
Open$5.02
Previous Close$5.08
Day High$5.31
Day Low$5.00
52W High$15.74
52W Low$1.55
Volume—
Avg Volume141.7K
Market Cap23.50M
P/E Ratio—
EPS$-18.75
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+593.9% upside
Current
$5.08
$5.08
Target
$35.25
$35.25
$27.20
$35.25 avg
$53.45
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.98M | 7.00M | 7.72M |
| Net Income | -1,326,181 | -1,545,557 | -1,571,652 |
| Profit Margin | -19.0% | -22.1% | -20.4% |
| EBITDA | -1,878,590 | -1,945,549 | -2,406,257 |
| Free Cash Flow | -1,092,947 | -1,597,568 | -1,077,092 |
| Rev Growth | +10.9% | +1.3% | +2.5% |
| Debt/Equity | 0.21 | 0.18 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |